THE REMOVAL OF CIRCULATING TOXINS DURING HEMODIALYSIS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 肾功能衰竭患者循环中有过多的有害分子和促炎细胞因子，需要进行血液透析治疗。我们已经确定了三种可能的蛋白，它们可能刺激和维持这些患者的炎症状态：高迁移率族蛋白-1(HMGB-1)、游离血红蛋白和S100A8。这项研究将观察这三种分析物在透析治疗过程中的循环水平。然后，这项研究将把循环中这些分析物的浓度与患者的“幸福感”联系起来，正如一份简短的问卷所描述的那样。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients with renal failure have an overabundance of many harmful molecules and proinflammatory cytokines in circulation and are treated by hemodialysis. We have identified three putative proteins that have the potential for stimulating and maintaining an inflammatory state in these patients: high mobility box group-1 (HMGB-1), free hemoglobin, and S100A8. This study will look at the circulating levels of these three analytes over the course of dialysis treatment. The study will then correlate the concentrations of these analytes in circulation with the patients' feeling of "well-being", as described by a short questionnaire.